Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Income towards Parent Company (2024 - 2025)

Kairos Pharma's Income towards Parent Company history spans 2 years, with the latest figure at -$1.4 million for Q2 2025.

  • For Q2 2025, Income towards Parent Company fell 507.69% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$4.1 million, down 42.27%, while the annual FY2025 figure was -$5.4 million, 129.06% down from the prior year.
  • Income towards Parent Company reached -$1.4 million in Q2 2025 per KAPA's latest filing, down from -$1.3 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$234000.0 in Q2 2024 to a low of -$1.4 million in Q4 2024.